As GSK3 inhibition and genetic knock-down enhanced NRF2 function, we next examined if NRF2 protein levels and NRF2 activity could be antagonised by GSK3 overexpression (as seen in type 2 diabetes). This evidence concerns the gene NFE2L2 and type 2 diabetes mellitus.